By Michael Erman NEW YORK (Reuters) U.S. drug prices fell again in the second quarter, likely due to a new tactic insurers are using to limit financial assistance drugmakers provide directly to consumers, according to research firm Sector and Sovereign Research (SSR) Real U.S. drug prices, which includes discounts and rebates drugmakers provide to insurers […]
Related Articles
The post Insurance Tactic Drags Down U.S. Drug Prices in Second Quarter: Analyst appeared first on OMG News Today.